Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (391-400 of 523) with videos related to

Pageof 53
Sort By:
Arthritis Care & Research|August 18, 2019
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II TrialPhilip S Helliwell, Atul Deodhar, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.
BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.
Annals of the Rheumatic Diseases|February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsArthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Nature Reviews. Disease Primers|November 25, 2016
PsoriasisJacqueline E Greb, Ari M Goldminz, James T Elder, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2023
Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature reviewS E Choon, C De La Cruz, P Wolf, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Streamlining Psoriatic Arthritis Screening and Management Using the IDEOM Clinical Framework: A Quality Improvement InitiativeSarah Romanelli, Gretchen D Ball, Hassan Hamade, et al.
Annals of the Rheumatic Diseases|February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialChristopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
Pageof 53

Showing results (391-400 of 523) with videos related to

Sort By:
Pageof 53
Arthritis Care & Research|August 18, 2019
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II TrialPhilip S Helliwell, Atul Deodhar, Alice B Gottlieb, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.
BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.
Annals of the Rheumatic Diseases|February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trialsArthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Nature Reviews. Disease Primers|November 25, 2016
PsoriasisJacqueline E Greb, Ari M Goldminz, James T Elder, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2023
Health-related quality of life in patients with generalized pustular psoriasis: A systematic literature reviewS E Choon, C De La Cruz, P Wolf, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Streamlining Psoriatic Arthritis Screening and Management Using the IDEOM Clinical Framework: A Quality Improvement InitiativeSarah Romanelli, Gretchen D Ball, Hassan Hamade, et al.
Annals of the Rheumatic Diseases|February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialChristopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
Pageof 53